After the COVID-19 pandemic—Which new vaccinations for adults are available or coming soon? Nach der COVID-19-Pandemie – welche neuen Impfungen im Erwachsenenalter sind schon oder bald verfügbar?
Kwetkat A, Leischker A, Endres AS, Heppner HJ (2023)
Publication Type: Journal article
Publication year: 2023
Journal
DOI: 10.1007/s00108-023-01640-9
Abstract
The accumulation of respiratory infections in the winter months repeatedly highlights the relevance of prevention through vaccination, even beyond a pandemic. Current developments in this field are therefore highly relevant, particularly for older people who are more susceptible to infections due to immune senescence and comorbidities. The Standing Committee on Vaccination (STIKO) has responded accordingly by recommending the 20-valent pneumococcal conjugate vaccine PCV20 for standard and indication vaccination of adults. Furthermore, new vaccines against respiratory syncytial virus (RSV) infections are available for which the STIKO has not yet issued a recommendation. The development of other more effective and more immunogenic vac2cines is being driven in particular by new technologies, such as mRNA or vector vaccines. Various higher valent pneumococcal vaccine candidates and, for example, universal influenza vaccines are also already in development.
Involved external institutions
Germany (DE)How to cite
APA:
Kwetkat, A., Leischker, A., Endres, A.S., & Heppner, H.J. (2023). After the COVID-19 pandemic—Which new vaccinations for adults are available or coming soon? Nach der COVID-19-Pandemie – welche neuen Impfungen im Erwachsenenalter sind schon oder bald verfügbar? Innere Medizin. https://dx.doi.org/10.1007/s00108-023-01640-9
MLA:
Kwetkat, A., et al. "After the COVID-19 pandemic—Which new vaccinations for adults are available or coming soon? Nach der COVID-19-Pandemie – welche neuen Impfungen im Erwachsenenalter sind schon oder bald verfügbar?" Innere Medizin (2023).
BibTeX: Download